PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27437080-0	2016	Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.	MK-7145	13-20	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	45-49
29076349-5	2017	Efforts to develop small molecule Kir1.1 inhibitors produced MK-7145, which entered into clinical trials.	MK-7145	61-68	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	34-40
27437080-5	2016	These proof-of-biology studies established for the first time that the human and rodent genetics accurately predict the in vivo pharmacology of ROMK inhibitors and supported identification of the first small molecule ROMK inhibitor clinical candidate, MK-7145.	MK-7145	252-259	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	144-148
27437080-5	2016	These proof-of-biology studies established for the first time that the human and rodent genetics accurately predict the in vivo pharmacology of ROMK inhibitors and supported identification of the first small molecule ROMK inhibitor clinical candidate, MK-7145.	MK-7145	252-259	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	217-221
34038119-2	2021	Our first disclosed clinical ROMK compound, 2 (MK-7145), demonstrated robust diuresis, natriuresis, and blood pressure lowering in preclinical models, with reduced urinary potassium excretion compared to the standard of care diuretics.	MK-7145	47-54	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	29-33